Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 204.08M P/E - EPS this Y 47.20% Ern Qtrly Grth -
Income -89.91M Forward P/E -2.01 EPS next Y -1.50% 50D Avg Chg -8.00%
Sales 145.67M PEG 0.04 EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book N/A EPS next 5Y -30.30% 52W High Chg -70.00%
Recommedations 1.90 Quick Ratio 3.31 Shares Outstanding 124.68M 52W Low Chg 24.00%
Insider Own 6.08% ROA -31.98% Shares Float 123.03M Beta 0.19
Inst Own 56.70% ROE - Shares Shorted/Prior 17.93M/18.26M Price 1.79
Gross Margin 89.19% Profit Margin -61.73% Avg. Volume 3,435,614 Target Price 4.36
Oper. Margin -65.72% Earnings Date Oct 31 Volume 2,225,002 Change -0.56%
About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc. News
11/20/24 Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
11/18/24 Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
11/08/24 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
11/06/24 Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/06/24 Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
11/05/24 Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript
11/05/24 Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
11/05/24 Karyopharm Therapeutics: Q3 Earnings Snapshot
11/05/24 Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
11/01/24 Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/01/24 Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
10/31/24 Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
10/31/24 Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
10/31/24 Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
10/30/24 Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
10/25/24 Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares
09/05/24 Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
09/03/24 Karyopharm to Participate at Upcoming Investor Conferences
09/02/24 Pipeline Moves: Investigator-led oncology cell therapy trial terminated
08/09/24 With 58% ownership, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) boasts of strong institutional backing
KPTI Chatroom

User Image seforim Posted - 12 hours ago

$INCY $KPTI $NVS $GSK $ABBV https://x.com/kinatsofrim/status/1860028319384895605

User Image celebratelife Posted - 15 hours ago

$KPTI Insider tells us they've had layoffs, which is good. Elhan Webb was likely laid off. IR's been useless b/c of reporting to Mason.

User Image seforim Posted - 1 day ago

$KPTI https://x.com/kinatsofrim/status/1726977230134558759

User Image celebratelife Posted - 1 day ago

$KPTI

User Image celebratelife Posted - 1 day ago

$KPTI

User Image seforim Posted - 1 day ago

$KPTI https://x.com/kinatsofrim/status/1833923683745939851

User Image celebratelife Posted - 1 day ago

$KPTI

User Image JuggernautRaider Posted - 1 day ago

$CDT seems to be the real deal. The Japanese market is huge from an IP perspective- if Phase 3 trials are successful there with Japanese patients, then it is a MAJOR $$$ market. One of $KPTI’s major failings was not pursuing an approval for Xpovio in Japan. @NoorAlTrades and @DoctorDueDiligence know that Richard Paulson is a FRAUD. He should be FIRED. And both Barry Greene and Garen Bohlin should be kicked off the board too! 1) sell $AMGN 2) hold $KPTI 3) buy $CDT ~ smart business model with a REAL CEO in David Tapolczay https://www.globenewswire.com/news-release/2024/11/21/2985121/0/en/Conduit-Pharmaceuticals-Receives-Further-Patent-Approval-For-Lead-Asset-Targeting-Autoimmune-Disorders.html

User Image klem817 Posted - 1 day ago

$KPTI down trend stay .6 it come

User Image seforim Posted - 1 day ago

$KPTI $NVS https://x.com/Seank4384/status/1859615243325870557

User Image seforim Posted - 1 day ago

$KPTI $ABBV $MRK $INCY $GSK https://x.com/kinatsofrim/status/1859619451772998019

User Image seforim Posted - 1 day ago

$KPTI $INCY $GSK $NVS $ABBV Myelofibrosis landscape timeline - thread https://x.com/kinatsofrim/status/1768375601847501223

User Image celebratelife Posted - 2 days ago

Party hardy in Barcelona. $KPTI This is how the KaryoFUN live-it-up spending-diarrhea Paulson/Greene vacation club "culture" burns through our cash and benefits insiders at our cost. Party hardy in Barcelona. Was it really necessary for Richard Paulson to be there? No. Smart companies send one or two reps max at minimal cost and bring in the knowledge back and share it. Not at KaryoFUN. Burn-baby-burn-through-investor-cash. This is just one of many examples how Richard Paulson's mismanagement debilitated the company, with endorsement from Barry Greene et al at the useless Board who should not be Directors of any Board Ever, given their destruction of KPTI by their horrible "leadership".

User Image celebratelife Posted - 2 days ago

$KPTI Seems Elhan Webb has been laid off. They are calling it "resignation" which would be dishonest (asking someone to resign is not a resignation) - just as the case of Mike Mason the disaster CFO that the horrible CEO Richard Paulson so much praised. Why would these people "resign" from the easiest "job" in the world if you can call it that, at the Richard Paulson "vacation club" with endless benefits and "work" from anywhere all the time, 4.5 day work, daily free lunches, more vacation than most US companies, paid time off for many occasions including volunteering! and so on, all on our tab because Paulson's culture has chronic spending diarrhea, and the Board has failed its duties for too long resulting in 96% drop in value. Mike Mason got some $60,000 a month for doing nothing that ever added value (market cap) to the company. People with these jobs don't "resign", they get fired or laid off to put it politely. Elhan is a nice lady but as head of IR she was totally restrained by her boss, Mike Mason who has no clue what effective IR is - thus IR was a catastrophe (numbers don't lie). She's always been under Mike Mason's thumb - who micro manages investor communications because he's so nervous about his own job, and his role as gatekeeper to make sure the fat, lazy, do-nothing Board continues in the rotten status quo which makes itself richer and richer at the cost of investors, and in the process make people like Paulson and Mano richer by giving then undeserved fat salaries and bonuses while company value has been destroyed on their watch, by their mismanagement, it seems. But KaryoFUN has an unofficial leakage "IR" person: "Seforim" ("David" "Rabbenu Pehter" "Kinat Sofrim") https://x.com/kinatsofrim/photo who has been more effective than Elhan or the company in keeping investors informed of information that we wouldn't otherwise have - and it seems he gets his info from an internal source, real-time. On Nov 19 he posted: "Nov. 19, SVP of IR resigns & outsourced to Argot Partners." which the company has not announced itself. He's posted many such things in the past and links to interesting scientific developments that average investors wouldn't know, and even the company's calendar of events before it's officially released. This week he also posted that the company went to a conference in London where they didn't present, but were present (because Paulson likes to burn our money on himself). "What folks miss is that $KPTI mgmt is at Jefferies like they do every year... only difference is this year they aren't doing a fireside chat." The man is in the know. So much for SEC's RegFD. And you can bet, if "David" gets this insider info, others do too, which helps the shorts make sure there are no surprises. Just another rotten part of Paulson/Greene's vacation club "culture".

User Image seforim Posted - 2 days ago

$KPTI https://x.com/sak77328/status/1859415111259349003

User Image seforim Posted - 2 days ago

$KPTI https://x.com/kinatsofrim/status/1859404416626897311

User Image seforim Posted - 2 days ago

$KPTI https://x.com/kinatsofrim/status/1859397674706833917

User Image longrigger52 Posted - 2 days ago

$KPTI new head of accounting role is "interim". They didnt bring in an experienced cfo who can do debt deal or r/s split. Looks to me as a placeholder before BO, no ???

User Image celebratelife Posted - 2 days ago

$KPTI Fire Paulson and the stock will take off.

User Image klem817 Posted - 3 days ago

$KPTI .6 down trend it continue

User Image celebratelife Posted - 3 days ago

$KPTI Short-friendly Management & Board Still Engaged In Destroying Company Value.

User Image seforim Posted - 3 days ago

$INCY $KPTI https://x.com/kinatsofrim/status/1858961573936853454

User Image celebratelife Posted - 3 days ago

$KPTI @seforim: "Jefferies London Healthcare Conference November 19 in London". What happened?

User Image longrigger52 Posted - 3 days ago

$KPTI tax loss kicking in on a lot of shitty stocks

User Image PrettyBlob Posted - 3 days ago

$KPTI Crushing it as always!! Where my perma bulls at? How come you all fade away and I’m the inly one left?!? Oh that’s right, because this company is not capable of delivering. Not with the mgmt team. Sell. The. Company.

User Image TheRealStocksavior Posted - 3 days ago

$KPTI when’s the r/s coming? Gotta be somewhat soon right

User Image seforim Posted - 4 days ago

$KPTI $INCY https://x.com/kinatsofrim/status/1858650236241023469

User Image celebratelife Posted - 4 days ago

$KPTI

User Image wizard1863 Posted - 4 days ago

$KPTI $ZOM you really need to know what you own! ZOM isn’t even in the Nasdaq!

User Image longrigger52 Posted - 4 days ago

$KPTI POS

Analyst Ratings
HC Wainwright & Co. Buy Aug 7, 24
RBC Capital Outperform Aug 7, 24
Baird Outperform Aug 7, 24
HC Wainwright & Co. Buy Jun 28, 24
HC Wainwright & Co. Buy Jun 3, 24
HC Wainwright & Co. Buy May 9, 24
HC Wainwright & Co. Buy Mar 1, 24
Piper Sandler Overweight Nov 3, 23
RBC Capital Outperform Nov 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Paulson Richard A. President and CEO President and CEO Jan 04 Sell 0.82 4,114 3,373 783,465 01/08/24
Paulson Richard A. President and CEO President and CEO Dec 04 Sell 0.79 3,622 2,861 787,579 12/05/23
Paulson Richard A. President and CEO President and CEO Nov 06 Sell 0.9203 3,606 3,319 791,201 11/07/23
Paulson Richard A. President and CEO President and CEO Oct 04 Sell 1.27 3,589 4,558 794,807 10/05/23
BOHLIN GAREN G Director Director Sep 12 Buy 1.215 41,140 49,985 45,140 09/12/23
Paulson Richard A. President and CEO President and CEO Aug 07 Sell 1.72 3,722 6,402 802,018 08/08/23
Poulton Stuart EVP, Chief Developme.. EVP, Chief Development Officer Jul 28 Sell 1.70 2,845 4,836 156,286 08/01/23
Paulson Richard A. President and CEO President and CEO Jul 05 Sell 1.72 3,538 6,085 805,740 07/06/23
Rangwala Reshma EVP & Chief Medical.. EVP & Chief Medical Officer Apr 20 Sell 4.04 6,770 27,351 158,230 04/24/23
Paulson Richard A. President and CEO President and CEO Apr 04 Sell 3.97 3,497 13,883 816,619 04/05/23
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 28 Sell 3.03 11,205 33,951 245,361 03/02/23
Paulson Richard A. President and CEO President and CEO Feb 28 Sell 3.03 33,033 100,090 823,622 03/02/23
Paulson Richard A. President and CEO President and CEO Dec 05 Sell 5.17 3,490 18,043 612,527 12/06/22
Paulson Richard A. President and CEO President and CEO Nov 04 Sell 4.54 3,493 15,858 616,017 11/08/22
Paulson Richard A. President and CEO President and CEO Sep 08 Sell 5.24 3,479 18,230 622,998 09/09/22
Greene Barry E Director Director Aug 11 Option 1.485 7,576 11,250 13,606 08/15/22
Cheng Sohanya Roshan Chief Commercial Off.. Chief Commercial Officer Jun 13 Sell 5.27 1,551 8,174 89,949 06/14/22
PAKIANATHAN DEEPIKA Director Director Jun 08 Sell 6.23 538,784 3,356,624 16,673 06/10/22
Paulson Richard A. President and CEO President and CEO Jun 07 Sell 5.7602 2,542 14,642 630,906 06/08/22
Mason Michael EVP, CFO, Treasurer EVP, CFO, Treasurer Jun 03 Sell 6.05 601 3,636 138,509 06/06/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 28 Sell 10.24 12,452 127,508 713,757 03/02/22
Kauffman Michael Director Director Feb 28 Sell 10.24 12,452 127,508 898,131 03/02/22
Kauffman Michael Director Director Feb 17 Sell 12.12 18,167 220,184 904,357 02/22/22
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 07 Sell 9.862 1,704 16,805 130,756 02/09/22
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 07 Sell 9.862 1,991 19,635 104,632 02/09/22
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 07 Sell 9.862 3,947 38,925 53,308 02/09/22
Kauffman Michael Director Director Feb 07 Sell 9.86 13,471 132,824 913,445 02/09/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 07 Sell 9.86 13,471 132,824 708,062 02/09/22
Shacham Sharon President & CSO President & CSO Feb 22 Sell 14.83 18,990 281,622 575,126 02/22/21
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 17 Sell 15.52 1,748 27,129 48,127 02/17/21
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 17 Sell 15.52 2,046 31,754 39,338 02/17/21
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Feb 17 Sell 15.52 13,243 205,531 764,147 02/17/21
Mirza Mansoor Raza Director Director Dec 22 Sell 18 5,000 90,000 12/22/20
Mirza Mansoor Raza Director Director Dec 22 Option 5.43 5,000 27,150 5,000 12/22/20
Lewis Tanya EVP,Chief Reg.&Quali.. EVP,Chief Reg.&Quality Officer Nov 04 Sell 15.58 226 3,521 539 11/04/20
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Nov 04 Sell 19.46 589 11,462 43,229 11/04/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Option 9.8 39,271 384,856 5,370 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Sell 17.03 39,271 668,785 4,649 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Option 6.54 10,054 65,753 14,703 09/10/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Sell 14.98 10,054 150,609 4,649 09/10/20